Pharma Faces $200-300 Billion Patent Cliff Through 2032 as Blockbusters Lose Exclusivity
Feb 16, 2026
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.